Beteiligung am Exzellenzcluster

CiM-Professor für Translationale Onkologie

  • Forschungsgebiet A.2: Programmiertes Zellschicksal und Plastizität von pluripotenten und somatischen Stammzellen
  • Projekt FF-2016-10: The diagnostic and prognostic value of FDG-PET-MRI and its correlation with cellular and biologic features in primary CNS lymphoma patients (Georg Lenz, Oliver Grauer, Werner Paulus, Michael Schäfers, Projektlaufzeit: 07/2016 - 06/2018)
© CiM - Peter Grewer

„Es ist mein Ziel, maligne Lymphome auf einer molekularen Ebene zu behandeln“

CiM-Prof. Georg Lenz ist Spezialist für Lymphdrüsenkrebs, sowohl als Arzt als auch als Wissenschaftler. Von seiner Forschung profitieren auch seine Patienten. Denn er bringt seine aktuellsten Erkenntnisse auch in die Klinik. Zum Interview

CiM-Publikationen

alle Publikationen von Georg Lenz

2017

Dai B, Grau M, Juilland M, Klener P, Horing E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Johrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 2017;129: 333-346. Abstract
Erdmann T, Klener P, Lynch JT, Grau M, Vockova P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 2017;130: 310-322. Abstract
Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Kessler T, Kerkhoff A, Lenz G, Berdel WE. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Res Treat 2017;49: 548-552. Abstract
Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Gorlich D, Marra A, Hillejan L, Muller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwoppe C, Hartmann W. Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS One 2017;12: e0177146. Abstract
Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer 2017;113: 121-127. Abstract
Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann M-L, Kreher S, Kochert K, Krappmann D, Klapper W, Hummel M, Wenzel S-S, Lenz G, Janz M, Dorken B, Siebert R, Mathas S. Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia 2017;31: 602-613. Abstract

2016

Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, Lenz G, Hauck SM, Krappmann D. Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas. Oncogene 2016;35: 4269-4281. Abstract
Erdmann T, Lenz G. Approaching resistance to ibrutinib in diffuse large B-cell lymphoma. Leuk Lymphoma 2016;57: 1254-1255. Abstract
Gatjen M, Brand F, Grau M, Gerlach K, Kettritz R, Westermann J, Anagnostopoulos I, Lenz P, Lenz G, Hopken UE, Rehm A. Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. Cancer Res 2016;76: 5253-5265. Abstract
Juilland M, Gonzalez M, Erdmann T, Banz Y, Jevnikar Z, Hailfinger S, Tzankov A, Grau M, Lenz G, Novak U, Thome M. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood 2016;127: 1780-1789. Abstract
Lange J, Lenz G, Burkhardt B. Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. Expert Rev Hematol 2016: 1-13. Abstract
Lenz G. Novel NF-kappaB regulator in ABC DLBCL. Blood 2016;127: 2785-2786. Abstract
Pohlen M, Groth C, Sauer T, Gorlich D, Mesters R, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Berdel WE, Stelljes M. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). Bone Marrow Transplant 2016;51: 1441-1448. Abstract
Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch J-H, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Gorlich D, Berdel WE. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Haematologica 2016;101: 1208-1215. Abstract
Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Groning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Muller-Tidow C, Rosenbauer F. Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. Embo J 2016;35: 2399-2416. Abstract
Stucke-Ring J, Ronnacker J, Brand C, Holtke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wunsch B, Muller-Tidow C, Mesters RM, Schwoppe C, Berdel WE. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget 2016;7: 82458-82472. Abstract
Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G. The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma 2016: 1-8. Abstract

2015

Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G, Ruland J. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci U S A 2015;112: E7230-8. Abstract
Lenz G. Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers (Basel) 2015;7: 811-822. Abstract
Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dorken B, Chu Y-W, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015;29: 1578-1586. Abstract
Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dorken B, Dirnhofer S, Mathas S, Janz M, Emre NCT, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 2015;125: 124-132. Abstract